FAS and endometrial carcinoma: Sorafenib, a broad-spectrum kinase inhibitor targeting the RAF–MEK–ERK pathway, enhanced sensitization to TRAIL- or FAS-mediated apoptosis by downregulation of cFLIP in endometrial carcinoma cell lines that are resistant to TRAIL or FAS [130].